Categories: News

Izotropic Provides Update on Annual General Meeting Materials and Voting Procedures

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Vancouver, British Columbia–(Newsfile Corp. – December 4, 2024) – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic” or the “Company“), a medical device company commercializing IzoView, a CT (computed tomography) imaging system, announces that due to the suspension of mail service in Canada due to the nationwide strike of the Canadian Union of Postal Workers, that the notice of meeting, information circular, requests for financial statements and proxy form (the “Meeting Materials“) for the Company’s upcoming Annual General Meeting will not be mailed and have been posted and are accessible on the Company’s SEDAR+ profile and on the Company’s website at https://izocorp.com/investors/agm/.

Shareholders may access the meeting materials at the aforementioned websites and can contact the Company at ir@izocorp.com to obtain their voting control numbers that will be available on or before December 9, 2024, to vote their shares online at https://vote.odysseytrust.com.

Registered and beneficial shareholders who have provided prior e-consent to either Izotropic’s trust company, Odyssey Trust, or their brokerage house, depository company or other intermediary with which they hold their shares will receive their meeting materials, instructions on how to vote, and voting control number via email from the organization in which their shares are held to vote their shares online at https://vote.odysseytrust.com.

Copies of the Company’s annual audited, and quarterly interim financial statements and management’s discussion and analysis are accessible on the Company’s Sedar+ profile and on the Company’s website at https://izocorp.com/investors/financials/.

ON BEHALF OF THE BOARD

Mr. Robert Thast, CEO
Cell: 604-220-5031

Contact:
Email: info@izocorp.com
Toll Free: 1-833-IZOCORP ext.1

About Izotropic
More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com.

Forward-Looking Statements
This document may contain statements that are “Forward-Looking Statements,” which are based upon the current estimates, assumptions, projections, and expectations of the Company’s management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as “anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate” and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.

These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company’s activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/232512

Staff

Recent Posts

SCAN Named the Winner of the 2025 Hearst Health Prize

$100,000 Hearst Health Prize recognizes innovative initiatives using data science to make a health impact…

2 hours ago

Nanalysis Announces First Quarter 2025 Results

Delivers Another Quarter of Positive Adjusted EBITDA & Operating Cash Flow CALGARY, AB, May 28,…

2 hours ago

Veeva Announces Fiscal 2026 First Quarter Results

Total Revenues of $759.0M, up 17% Year Over YearSubscription Services Revenues of $634.8M, up 19%…

2 hours ago

Staffency, a TotalMed Company, Announces Merger with SimpliFi to Enhance Workforce Solutions

APPLETON, Wis., May 28, 2025 /PRNewswire/ -- Staffency, a premier workforce solutions provider and division…

2 hours ago

World-Renowned Mold Illness Expert Dr. Scott McMahon Joins MoldCo as Medical Director

Together, They Aim to Solve One of America's Most Overlooked Health Crisis: Mold Toxicity LOS…

2 hours ago

SimpliFi Announces Merger with Staffency, a TotalMed Company, to Enhance Workforce Solutions

LITTLE ROCK, Ark., May 28, 2025 /PRNewswire/ -- SimpliFi, a premier workforce solutions provider and…

2 hours ago